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Neutrophil extracellular traps (NETs) comprise neutrophil DNA, citrullinated (deiminated) 
histones, and proteases (1, 2). NET formation in vivo mostly occurs at the sites of inflammation. 
Neutrophils, adhering to the endothelium or after extravasation, generate NETs upon interaction 
with microbes, activated platelets, cytokines, alarmins, such as high-mobility group box 1 (HMGB1), 
or uric acid. Environmental cues, such as hyperosmolarity or hyperglycemia, neurotransmitters, and 
some autoantibodies also trigger NET generation (3–7). In vitro, two main pathways are activated: 
suicidal and vital NETosis (8). In the former, membrane integrity is disrupted and neutrophils die. 
In contrast, after “vital” NETosis neutrophils still migrate, chase bacteria, and extrude residual 
nuclear material through exocytosis (9). Generation of reactive oxygen species (ROS) and fusion of 
neutrophil primary granules with the nuclear membrane that promote interactions between elastase, 
myeloperoxidase (MPO), and DNA are features of suicidal NETosis. Their role in vital NETosis is 
debated (8, 10–12). Activation of the autophagic pathway is intermingled with NET generation. 
Autophagy sustains the metabolic requirements of the extensive intracellular vesicular formation, 
transport, and fusion associated with NET generation. It also sustains neutrophil survival (5).
Neutrophils undergo extensive ex vivo manipulations and methodological approaches vary 
among research groups, possibly explaining some discrepancies and nurturing some healthy skepti-
cism (13). Some reports indicate a role of the mitochondrial DNA, which is devoid of histones, in 
NET generation. The relative contribution of nuclear vs. mitochondrial DNA to extracellular traps 
generation remains a controversial issue (14).
Under physiological conditions, NETs enhance the host response to microbes by (i) providing 
a template concentrating humoral innate immune molecules, such as pentraxin 3 (PTX3) and 
complement, together with microbicidal molecules, such as histones, MPO, proteinase 3 (PR3), or 
cathelicidin, and (ii) contrasting the hematogenic spread of pathogens through immunothrombosis 
(i.e., activation of platelets and of the coagulation cascade through NET components) (15). The 
actions of NET-embedded von Willebrand factor, of citrullinated histones, and of negative charges 
on platelet recruitment/activation and on the progression of the coagulation cascade contribute to 
thrombosis. Excellent reviews on this issue have been published (16, 17). The bioactive molecules 
integrated within the chromatin threads may vary according to the inciting stimuli or the environ-
ment. The characterization of the NETs proteome is a fascinating challenge for the near future.
Neutrophils are abundant in the blood, and their concentration and activation state increase 
following surges of systemic cytokines during acute phase responses. Thus, NETs are readily available 
and easily renewable tools for the first-line response to infectious agents. However, there is a price 
to pay. During acute infections (e.g., during sepsis), NETs favor progression toward septic shock, 
disseminated intravascular coagulation, and acute respiratory distress syndrome (ARDS), as well as 
tissue damage and organ failure, possibly because of the deleterious effects of immunothrombosis. 
On the other hand, the imbalance between the rate formation and degradation of NETs might favor 
the persistence and the presentation of autoantigens and facilitate autoimmunity (1).
2Ramirez et al. Let Us Bet on NETs
Frontiers in Immunology | www.frontiersin.org October 2016 | Volume 7 | Article 417
Systemic lupus erythematosus (SLE) is a paradigm of the 
pathogenic continuum that links nuclear antigens exposure 
to autoimmunity. Neutrophil from patients with SLE show 
prolonged survival (possibly through enhanced autophagy) and 
are thus endowed with additional chances to generate NETs. In 
addition, the clearance of extracellular DNA in SLE is impaired 
either as a genetically determined trait influencing waste dis-
posal or due to antibodies toward regulatory molecules, such as 
DNases (18, 19).
Antineutrophil cytoplasmic antibodies (ANCA) represent 
a variant on the theme of autoantibodies elicited following 
enhanced generation and/or persistence of NETs. The formation 
of NETs at sites of vascular inflammation in ANCA-associated 
vasculitides (AAV) and the ability of ANCA to perpetuate the 
generation of NETs were described in 2009 (3). Later on, dendritic 
cells have been found to capture ANCA targets (i.e., MPO and 
PR3) from NETs and to present them to T lymphocytes, while the 
susceptibility to ANCA generation was found to be deeply rooted 
in genetics. Neutrophil priming with HMGB1, a well-established 
inducer of NETs and of autophagy, contributes to the action of 
ANCA (20).
In rheumatoid arthritis, NETting neutrophils infiltrate the 
synovium and rheumatoid nodules, while anti-citrullinated 
peptides antibodies apparently boost the generation of NETs 
(21). B cells that expand and differentiate within ectopic synovial 
germinal centers frequently target deiminated antigens generated 
during NETosis (22, 23) and/or as a consequence of the release of 
bioactive peptidylarginine deiminases in the synovial fluid.
Anti-phospholipid antibodies in combination with ROS and 
platelet-assisted TLR4 stimulation induce neutrophils to form 
NETs, which in turn precipitate intravascular thrombosis (15). 
Conversely, NET degradation appears to be impaired in a fraction 
of patients with anti-phospholipid syndrome (19). Neutrophils 
infiltrate the pancreas of patients with type 1 diabetes mellitus 
(T1DM) (24) and, according to experimental models and indirect 
clinical evidence (systemic levels of NETs by-products in serum), 
cause an IFNα response, autoantibody generation, and β-cells 
destruction through in situ NETosis (25, 26).
inDiCATORS AnD MARKERS OF nETosis
The notion that NETs contribute to a wide range of autoimmune 
diseases so far has had little impact on the clinical practice. 
Reasons include
 (i) the low threshold of activation of neutrophils, which limits 
the development of robust, easy-to-perform, and cheap 
diagnostic assays;
 (ii) high costs of clinical trials; and
(iii) the lack of insight on appropriate targets to safely target 
NETosis.
Three main approaches are currently used in research 
laboratories:
• analytical assays based on fluorimetry for cell-free DNA or on 
ELISAs for soluble NET by-products (DNA–MPO or DNA–
neutrophil elastase complexes, citrullinated histones) (3, 5);
• confocal microscopy for neutrophil enzymes along extracellu-
lar DNA lattices (3, 5); and
• flow cytometry, based on nuclear morphology and variations 
in MPO distribution (11) or staining of citrullinated histones 
or DNA (27).
Fluorimetry is not time-consuming and generate semi-
quantitative information that can be associated with clinical 
variables. However, it does not unambiguously identify the 
source of DNA (neutrophils or other cells) or the process by 
which DNA was released (NETosis, necrosis, necroptosis, etc.). 
The association of DNA fragments to neutrophil enzymes and 
the citrullination of histones are relatively specific for NETosis. 
Thus, determination of MPO–DNA complexes and/or of 
citrullinated histones selectively reveals the amount of NET 
by-products in biological fluids. Human studies monitoring 
in vivo NETs formation (3, 5) also revealed a concordant rise 
in NETs by-products in plasma, suggesting that ELISA is suf-
ficient per se to assess the degree of NET formation in human 
inflammatory diseases (Figures  1A–F). Furthermore, parallel 
quantitation of in  vitro-generated NETs by confocal micros-
copy and concomitant measurement of DNA, DNA–MPO 
complexes, and citrullinated histones in cell-free supernatants 
drives to concordant results (Figures 1G–I). Thus, we believe 
that, at present, only ELISA assays on plasma samples meet the 
requirements of robustness, reproducibility, and easiness for 
widespread clinical use.
However, it does not discriminate between vital or suicidal 
NETosis nor assess the relative contribution of NET generation 
and catabolism. Standardized protocols will be necessary for 
transfer these assays to the clinics (28). For example, DNases for 
sample enrichment influence the sensitivity of MPO/DNA-based 
analytical assays (Figures 1G,H).
Microscopy allows a direct visualization of NETs. In expert 
hands, it remains a powerful and informative tool, even more 
when combined with the determination of NET by-products 
(Figures  1A–F) (3, 5) and with high-throughput proteomic 
assays. However, due to the high inter-observer variability, it 
is not routinely used in clinical practice. Novel semi-automated 
image analysis techniques might circumvent this limit. Flow 
cytometry yields accurate and reproducible data. Large trials 
are needed to pave the way to their widespread use (11, 28). 
Besides improvements in NET detection, caution in the pre-
analytical sample handling is mandatory, since neutrophils and 
platelets respond to physical and chemical stimuli during blood 
sampling and transportation. Activated platelets, in particular, 
release various signals – both soluble and associated with 
 microparticles – that impact on neutrophil functions, including 
NET generation (12, 29).
nETs, DRUG DEVELOpMEnT,  
AnD REpOSiTiOninG
Citrullination of histone residues is a key step in NETosis. 
Pharmacological or genetic tools to inhibit deiminating enzymes 
reduce the formation of NETs and their detrimental consequences 
in preclinical models (30–32). The actual selectivity and potential 
FiGURE 1 | nETs by-products are easily detected in the plasma of patients ongoing acute myocardial infarction and reflect the nETs that 
characterized coronary thrombi. (A–F) Coronary thrombi and plasma samples were obtained from 26 consecutive patients with STEMI underwent percutaneous 
intervention within 1–6 h from the onset of chest pain. NETs by-products were determined in plasma samples (anticoagulated with EDTA, venipuncture through a 
19-gage butterfly needle) and processed within 15 min of sampling. Whole blood was centrifuged 15 min (320 g; 4°C), and retrieved plasma was further centrifuged 
(5 min at 100,000 g, 4°C) to eliminate any cellular debris. Obtained plasma was then aliquoted and frozen until de-determination of NETs by-products. All steps of 
samples preparation were performed in sterile conditions. (A,B) The amount of DNA–MPO complexes and the quantification of histone H4 citrullinated were 
assessed in the plasma samples of the same AMI patients in which were analyzed the composition of coronary thrombi, patients with chronic stable angina (CSA) 
candidates for coronary revascularization, and sex- and age-matched healthy donors. (C–F) Representative confocal analysis of coronary thrombi of AMI patients 
obtained during revascularization procedure. NETs were identified as DNA lattices with evident citrullination of histones (C,D) and by the presence of specific 
neutrophil proteins such as PTX3 (E). We consistently detected the presence of NETs in close proximity of platelets (D–F) that frequently express HMGB1 (F) 
[adapted from Maugeri et al. (5)]. (G,H) The use of DNAs impaired the sensitivity on NET determination: addition of DNase seems useful when low numbers of 
neutrophils are used. Freshly purified human neutrophils (0.5–5 × 106) of healthy donors were placed on poly-l-lysine-coated slides for 20 min at 37°C, then were 
challenged with PMA (100 ng/mL) for 20 min at 37°C. Then, treated or not with DNase I, after incubation plates were centrifuged 5 min (320 g; 4°C), supernatants 
were retrieved and further cleared (5 min at 100,000 g) and frozen until determination of NETs by-products and cell-free DNA as we previously described [adapted 
from Maugeri et al. (5)]. (i) Quantitative assays for NET formation. The results of a series of independent experiments carried out with cells of different donors are 
presented in this back-to-back comparison of different quantitative assays to estimate the degree of NET generation. Neutrophils were stimulated with a large panel 
of agonists to reproduce the environmental variability that occurs under physiological conditions. Quantitation of cell-free DNA is consistent with the degree of NET 
generation as estimated by direct microscopy visualization and MPO/DNA- or citrullinated histone-based techniques in this set of experiments, where purified 
neutrophils were employed [adapted from Maugeri et al. (5)].
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safety risks of the available pharmacological inhibitors are not yet 
established.
Mitochondrial generation of ROS triggers NET formation. 
In  addition, oxidized mitochondrial DNA within NETs could 
contribute to its immunogenic potential. Interference with the res-
piratory chain and/or ROS scavenging exerts anti-inflammatory 
effects and clinical benefit in mice models of sepsis and SLE (33).
Targeting platelet/neutrophil reciprocal activation and 
platelet microparticle-associated moieties, HMGB1 in particular 
(5, 12, 34), and finding strategies aimed at restoring the phago-
cytosis of apoptotic substrates by neutrophils can exert a calming 
influence over NET generation (35) and thus appear promising. 
Other anti-NET treatments could aim at restoring and/or poten-
tiating the NET clearance. NET-mediated lung injury in cystic 
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fibrosis abates in response to nebulized DNase supplementation. 
Studies improving the drug delivery could pave the way for the 
application of this anti-NETs treatment to inflamed joints, kidney, 
lung, or skin in the setting of autoimmune diseases.
The repositioning of known drugs and agents has advantages 
over the development of new drugs, since toxicity/safety profiles 
are usually known and cost and time to bring agents to market 
abate. A proof-of-concept trial links reduced SLE flares to the 
metformin inhibition of mtDNA-enriched NETs. An action of 
metformin on HMGB1 release (5, 33) could also be involved. 
Heparins are being used in a wide range of diseases for effects 
independent of their anticoagulant properties (36), including 
conditions, in which NETs generation possibly plays a role. 
Heparins might interfere with the metabolic needs for NET 
generation since they restrict the activation of the autophagic flux 
(29). Prophylactic doses of low-molecular weight heparins, which 
are routinely used for thromboprophylaxis and for the prevention 
of pregnancy complications, indeed interfere with autophagy 
induction of neutrophils of healthy subjects and virtually abrogate 
the ability to generate NETs in response to various stimuli (29). 
Thus, interference with NETosis might be involved in the benefit 
of treatments selected mainly on empirical basis. Unfractionated 
heparin has also been shown to dismantle NETs after they have 
been generated, by liberating histones from the DNA backbone 
and destabilizing the chromatin threads (37).
In conclusion, accumulating data on the role of NETs in 
autoimmune diseases and in highly prevalent inflammatory con-
ditions such as sepsis demonstrate that novel bioindicators and 
treatments might readily become available and improve the qual-
ity of patients care from tomorrow. Its time to take the next step.
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